|
Real-time Estimate
Cboe BZX
12:58:28 23/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 34.51 USD | -8.92% |
|
-10.09% | +27.49% |
| 12:32am | Top Midday Decliners | MT |
| 12:21am | Celldex Therapeutics, Inc. - Special Call |
| Market Cap | 297.55Cr 260.03Cr 244.39Cr 223.02Cr 418.57Cr 28TCr 418.65Cr 2.93TCr 1.13TCr 15TCr 1.12TCr 1.09TCr 47TCr | P/E 2026 * |
-9.03x | P/E 2027 * | -8.9x |
|---|---|---|---|---|---|
| Enterprise Value | 231.32Cr 202.15Cr 189.99Cr 173.38Cr 325.4Cr 22TCr 325.46Cr 2.28TCr 879.88Cr 11TCr 868.69Cr 849.65Cr 36TCr | EV / Sales 2026 * |
1,139x | EV / Sales 2027 * | 219x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CLDX | Delayed | |
CBOE
| CLDX | Real-time | |
|
Tradegate
| TCE2 | Real-time | |
|
Deutsche Boerse AG
| TCE2 | Delayed | |
|
Boerse Muenchen
| TCE2 | Real-time | |
|
Börse Stuttgart
| TCE2 | Delayed | |
|
Berne S.E.
| TCE1 | End-of-day quote |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | -9.42% | ||
| 1 week | -10.09% | ||
| Current month | -12.63% | ||
| 1 month | -14.65% | ||
| 3 months | +3.64% | ||
| 6 months | +8.88% | ||
| Current year | +27.49% |
| 1 week | 30.39 |  | 41.62 |
| 1 month | 30.39 | | 42.12 |
| Current year | 22.33 | | 45.14 |
| 1 year | 22.1 | | 45.14 |
| 3 years | 14.4 | | 53.18 |
| 5 years | 14.4 | | 57.2 |
| 10 years | 1.5 | | 75.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 25/06/26 | Free | Executive/Senior Manager | 20,000 | 0.0255% | ||
| 25/06/26 | Free | Director | 26,000 | 0.0331% | ||
| 25/06/26 | Free | Chief Technology Officer | 57,000 | 0.0726% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.92% | -10.09% | +39.28% | +36.05% | 297.55Cr | |
| +2.55% | +4.77% | +4.07% | +32.02% | 4.67TCr | |
| +0.23% | +0.53% | +44.33% | +36.40% | 4.44TCr | |
| -0.22% | -5.95% | +333.84% | +542.23% | 4.13TCr | |
| +0.49% | +6.01% | +8.74% | +92.75% | 4.16TCr | |
| -1.60% | -0.17% | +9.73% | +43.63% | 3.01TCr | |
| +0.55% | +1.58% | +26.54% | +159.71% | 1.74TCr | |
| -0.64% | -1.25% | - | - | 1.56TCr | |
| +1.15% | +7.46% | +25.97% | +43.93% | 1.55TCr | |
| -1.29% | +12.21% | -10.03% | - | 1.41TCr | |
| Average | -0.80% | +2.72% | +53.61% | +123.34% | 2.7TCr | |
| Weighted average by Cap. | +0.25% | +1.89% | +68.66% | +142.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 20.31L 17.75L 16.68L 15.22L 28.57L 19Cr 28.58L 2Cr 77.26L 9.92Cr 76.28L 74.61L 32Cr | 1.07Cr 93.56L 87.93L 80.25L 1.51Cr 102.35Cr 1.51Cr 11Cr 4.07Cr 52Cr 4.02Cr 3.93Cr 168.5Cr |
| Net income | -32Cr -28Cr -26Cr -24Cr -45Cr -3.05TCr -45Cr -314.63Cr -121.41Cr -1.56TCr -119.86Cr -117.24Cr -5.02TCr | -36Cr -32Cr -30Cr -27Cr -51Cr -3.45TCr -51Cr -355.8Cr -137.29Cr -1.76TCr -135.55Cr -132.58Cr -5.68TCr |
| Net Debt | -66Cr -58Cr -54Cr -50Cr -93Cr -6.33TCr -93Cr -652.89Cr -251.93Cr -3.23TCr -248.73Cr -243.28Cr -10TCr | -63Cr -55Cr -52Cr -48Cr -89Cr -6.07TCr -89Cr -625.51Cr -241.37Cr -3.1TCr -238.3Cr -233.07Cr -9.99TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | $34.62 | -8.64% | 1,06,68,848 |
| 21/26/21 | $37.89 | -0.92% | 5,49,512 |
| 18/26/18 | $38.24 | -1.90% | 20,81,882 |
| 17/26/17 | $38.98 | +0.70% | 12,78,921 |
| 16/26/16 | $38.71 | +0.52% | 10,01,441 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CLDX Stock
Select your edition
All financial news and data tailored to specific country editions
